Core Viewpoint - Myriad Genetics has shown a positive trend in its stock performance, with shares increasing by approximately 4.1% since the last earnings report, outperforming the S&P 500. Investors are curious whether this trend will continue leading up to the next earnings release [1] Financial Performance - Myriad Genetics reported fourth-quarter 2025 adjusted earnings of 4 cents per share, exceeding the Zacks Consensus Estimate by 350% and reflecting a year-over-year increase of 33.3%. The GAAP loss per share was 8 cents, an improvement from a loss of 47 cents in the prior-year quarter [2] - For the full year, adjusted earnings were 6 cents per share, down from 14 cents in the previous year, while the Zacks Consensus Estimate projected flat earnings for 2025 [3] Revenue Analysis - Total revenues for the fourth quarter fell by 0.4% year over year to $209.8 million but surpassed the Zacks Consensus Estimate by 1.07%. Testing volumes increased by 2% year over year [4] - For the full year 2025, revenues totaled $824.5 million, a decline of 1.6% from the previous year, but slightly exceeded the Zacks Consensus Estimate by 0.3% [4] Segment Revenue Breakdown - In Q4, Hereditary Cancer testing revenues rose by 3% year over year to $96.8 million, while Tumor Profiling testing revenues increased by 2% to $31.5 million. Prenatal testing revenues remained flat at $44.9 million, and Mental Health revenues decreased by 10% to $36.6 million [5] Margin and Expense Performance - The gross margin decreased by 168 basis points to 70% due to a 5.5% rise in the cost of revenues. Research and development expenses fell by 14.1% year over year to $25.5 million, and SG&A expenses decreased by 16.4% to $55.6 million [6] - The adjusted operating loss was $3 million, significantly improved from a loss of $17.3 million in the year-ago quarter [6] Financial Position - Myriad Genetics ended Q4 2025 with cash and cash equivalents of $149.6 million, up from $102.4 million at the end of Q4 2024. Long-term debt increased to $119.9 million from $39.6 million in the previous year [7] - The cumulative net cash outflow from operating activities was $1.8 million, an improvement from an outflow of $8.7 million in the prior-year period [7] Future Guidance - Myriad Genetics reiterated its full-year 2026 revenue guidance, expecting revenues between $860 million and $880 million, with the Zacks Consensus Estimate at $867.5 million [8] - The full-year adjusted gross margin is anticipated to be in the range of 68%-69%, and adjusted EBITDA is forecasted between $37 million and $49 million [9] Analyst Sentiment - Analysts have not made any earnings estimate revisions in the last two months, resulting in a consensus estimate shift of -21.15% [10] - Myriad Genetics holds a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [12] Industry Comparison - Myriad is part of the Zacks Medical - Biomedical and Genetics industry. Competitor Moderna reported a revenue decline of 29.8% year-over-year, with an EPS of -$2.11 compared to -$2.50 a year ago [13] - Moderna is expected to post a loss of $2.03 per share for the current quarter, reflecting a year-over-year change of +19.4% [14]

Core Insights - Myriad Genetics, Inc. (MYGN) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, exceeding the Zacks Consensus Estimate by 350% and showing a year-over-year increase of 33.3% [1][8] - The company’s total revenues for Q4 2025 were $209.8 million, a slight decline of 0.4% year over year, but still surpassing the Zacks Consensus Estimate by 1.07% [3][8] - MYGN's shares surged by 21.7% in after-hours trading following the earnings announcement [3][8] Financial Performance - For the full year 2025, adjusted earnings were 6 cents per share, down from 14 cents in the previous year [2] - The gross margin for Q4 fell by 168 basis points to 70%, attributed to a 5.5% increase in the cost of revenues [5][8] - Research and development expenses decreased by 14.1% year over year to $25.5 million, while SG&A expenses dropped by 16.4% to $55.6 million [5] Revenue Breakdown - In Q4, Hereditary Cancer testing revenues increased by 3% year over year to $96.8 million, while Tumor Profiling testing revenues rose by 2% to $31.5 million [4] - Prenatal testing revenues remained flat at $44.9 million, and Mental Health revenues decreased by 10% to $36.6 million [4] Financial Position - At the end of Q4 2025, Myriad Genetics had cash and cash equivalents of $149.6 million, up from $102.4 million at the end of Q4 2024 [6] - Long-term debt increased to $119.9 million from $39.6 million at the end of Q4 2024 [6] - The cumulative net cash outflow from operating activities was $1.8 million, an improvement from an outflow of $8.7 million in the previous year [6] Future Guidance - Myriad Genetics expects 2026 revenues to be between $860 million and $880 million, with a Zacks Consensus Estimate of $867.5 million [9] - The company anticipates a full-year adjusted gross margin in the range of 68%-69% and adjusted EBITDA between $37 million and $49 million [9] Strategic Developments - The company is making progress in its cancer care continuum strategy, focusing on maintaining leadership in hereditary cancer testing while expanding into other cancer testing applications [10] - The newly launched expanded MyRisk panel has received positive market feedback, and the company is preparing to start commercial testing of PRECISE MRD for breast cancer [10]